TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02601157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-months DAPT
Description: Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1-year DAPT
Description: Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
Study: NCT00737776

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03113032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-SEC Pre-Surgical Care
Description: The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-SEC Pre-Surgical Care
Description: The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (\<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal pre-surgical care
Description: Routine pre-surgical care
Study: NCT04055675

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine dipstick test
Description: A sample of urine will be tested using a Mission Urinalysis Reagent Strip.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine dipstick test
Description: A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
Study: NCT03188159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
Study: NCT01503008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus Sustained Behavior Change system
Description: The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Description: Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
Study: NCT04474678

Intervention type: OTHER
Group type: OTHER
Intervention: My Logbook! - I know my way around!
Description: Special issues/booklets of My Logbook - I know my way around! - Every booklet is based on evidence-based interventions. It illustrates psychosocial and interdisciplinary processes in a standardized way, resulting in a practical guide (My Logbook) to accompany the child throughout all stages of oncological treatment.
Study: NCT05224115

Intervention type: OTHER
Intervention: [11C]CHDI-00485180-R
Description: Mutant huntingtin aggregate binding PET radioligand.

Intervention type: OTHER
Intervention: [11C]CHDI-00485626
Description: Mutant huntingtin aggregate binding PET radioligand.
Study: NCT00516113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paroxetine
Description: Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
Study: NCT02793726

Intervention type: PROCEDURE
Intervention: NMR
Description: NMR

Intervention type: PROCEDURE
Intervention: NMR
Description: NMR
Study: NCT00522873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg NETA / 1.0mg E2 (Activella)
Description: One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study: NCT05464797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulp therapy
Description: partial or complete removal of inflamed pulp tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulp therapy
Description: partial or complete removal of inflamed pulp tissue
Study: NCT02456155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placing nasal jejunal tube with ultrasound
Description: bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placing nasal jejunal tube endoscopically
Study: NCT01904409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80 mg IR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg SER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80 mg SER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 80mgIR/80mgSER tablet
Study: NCT00659061

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SPRINKLES
Description: Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
Study: NCT00079040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04669223

Intervention type: DEVICE
Group type: OTHER
Intervention: Seldinger chest drain insertion
Description: Different sizes of chest drain will be inserted with seldinger technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger chest drain insertion
Description: Different sizes of chest drain will be inserted with seldinger technique
Study: NCT03480152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Description: Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
Description: Patients will receive a messenger ribonucleic acid (mRNA)-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
Study: NCT04312308

Intervention type: OTHER
Intervention: Sample collection
Description: 1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional.
Study: NCT01308736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
Study: NCT04468061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion
Study: NCT02903160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: 50 kBq/kg IV monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: 25 mg/m2 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg PO daily
Study: NCT01889875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Grazax 75,000 SQ-T Phleum pratense

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK AluTard 225 Phleum pratense
Study: NCT02970981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT00523757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01754974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Study: NCT03880058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLI-F06
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formulation buffer
Description: Placebo treatment
Study: NCT03018236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol N-acetylcysteine
Description: 1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Placebo
Description: Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine N-acetylcysteine
Description: 1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine Placebo
Description: Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
Study: NCT03142529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colon lotion
Description: The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
Study: NCT01475435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non- surgical periodontal treatment
Description: scaling and root planning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non- surgical periodontal treatment
Description: scaling and root planning

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prophylaxis
Description: Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prophylaxis
Description: Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
Study: NCT01682408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
Description: 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Description: 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
Description: 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
Description: 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
Description: 1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150 mg ranitidine
Study: NCT00763113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard PS Knee
Description: Vanguard PS Knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard CR Knee
Description: Vanguard CR Knee
Study: NCT02977000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
Study: NCT02920892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: 12.5 mg - 100 mg oral suspension (liquid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: 12.5 mg - 100 mg oral suspension (liquid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension (liquid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Intervention
Description: All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Language Intervention
Description: All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Intervention
Description: All subjects will begin an intensive language intervention 2 months after starting treatment with AFQ056 or placebo and will continue the intervention through the end of the study.~The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.~The language intervention is designed to help parents learn and use verbally responsive interactional strategies more frequently and effectively throughout the course of their daily interactions with their children.
Study: NCT02107833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPRX-106
Study: NCT02356913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Study: NCT02519023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: all individuals will receive scheduled acetaminophen (1 gram every 6 hours),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: all individuals will receive scheduled ibuprofen (800 mg every 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
Study: NCT04486235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief waiting room pamphlet
Description: An experiential pamphlet including brief assessment questions and recommended questions for the participant to ask their physician based on their responses. Areas covered in the pamphlet include patients' knowledge of weight status and implications of weight, confidence in physicians' abilities to treat weight, stage of change for weight-related behaviors, and comfort in discussing their weight.